ClinicalTrials.gg
CompletedNCT00619099Updated Oct 24, 2013Results posted

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

A Phase 2 interventional study of decitabine and decitabine in Myelodysplastic Syndrome, sponsored by Eisai Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-24.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.

Enrollment
27th of 74
67 · median 43
Started
2008
with 5 others
Phase 2
36 of 75
5 open now
Registered
16th of 75
by date
Lead sponsor
7 of 75
Eisai Inc.

Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 27th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 36 in phase 2, and was the 16th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing decitabine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effectiveness and safety of two different dose schedules of DACOGEN® (decitabine) for Injection in patients with Myelodysplastic Syndromes (MDS).

Read the detailed description

This is a randomized open-label Phase 2 efficacy and safety study of two (2) subcutaneous (SQ) dosing schedules of decitabine in subjects with Low or Intermediate 1 Risk MDS. This study will be conducted in up to 6 study centers in the United States.

The primary efficacy outcome is the overall improvement rate. These two doses will be administered subcutaneously. The probability that one schedule is superior to the other will be estimated, and the level of toxicity for each schedule will also be evaluated.

03

Conditions studied

  • Myelodysplastic Syndrome

Keywords

  • Myelodysplastic Syndrome
  • Decitabine
  • Dacogen
  • MGI PHARMA, Inc.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet the following criteria to be enrolled in this study:

  1. Male or female patients age 18 years and older.
  2. Patients must sign an institutional review board (IRB)-approved form, and understand the nature of this study and its potential hazards prior to initiation of any study-specific procedures or treatment.
  3. Must have (ECOG) performance status of 0-2.
  4. Adequate renal and hepatic function (creatinine \< 2 times , total of \< 2 times upper limit of normal, and and ALT ≤ 2 times upper limit of normal) unless proven to be related to disease infiltration.
  5. Female patients need a negative serum or urine pregnancy test within 7 days prior to study drug administration (applies only if patient is of . Non-childbearing is defined as ≥ 1 year or surgically sterilized).
  6. Women of childbearing potential and men must use . Men and women must continue birth control for the duration of the study.
  7. Patients with Low or Intermediate-1 Risk MDS by the International Prognostic Scoring System (IPSS) classification.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study:

  1. Women who are pregnant or nursing.
  2. Those who have received prior therapy with decitabine.
  3. Prior therapy with azacitidine (Vidaza®).
  4. Those who received growth factor support or lenalidomide in the 30 days prior to the first dose of decitabine.
  5. Those who have received an agent 30 days prior to the first dose of decitabine.
  6. Patients with active, uncontrolled, systemic infection considered opportunistic, life threatening or ; or any severe, concurrent disease, which, in the judgment of the Investigator and after discussion with the Sponsor and Primary Investigator, would make the patient inappropriate for study entry.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    1

    Drug: decitabine

  • Experimental
    2

    Drug: decitabine

Interventions

  • Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.

    Also known as: Dacogen

  • Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.

    Also known as: Dacogen

06

What researchers measure

Primary outcomes

  1. The Overall Improvement Rate

    Defined as proportion of patients having complete remission (CR), partial remission (PR), marrow complete remission (mCR), or hematologic improvement. Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Remission: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 109/L; Neutrophils ≥ 1.0 X 109/Lb; Blasts 0%. Partial Remission: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by ≥ 50% over pretreatment but still \> 5%. Marrow Complete Remission: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR. HI Improvement: shown in increases in hemoglobin, platelet and neutrophil response.

    Time frame: Up to one year

07

Results

Posted Sep 18, 2013

Participant flow

This study was recruited at 5 centers in U.S. during the period of Jun 2008 to Aug 2011.

Participant flow — Overall Study
MilestoneSchedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 Days
Started4423
Received at least 2 cycles of treatment4322
Completed114
Not completed3319
Withdrew: Progressive disease75
Withdrew: Allogeneic bone marrow transplantation21
Withdrew: Adverse event43
Withdrew: Emergence of clinically significant lab12
Withdrew: Withdrawal by subject102
Withdrew: Physician decision96

Outcome measures

PrimaryThe Overall Improvement Rate

Defined as proportion of patients having complete remission (CR), partial remission (PR), marrow complete remission (mCR), or hematologic improvement. Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Remission: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 109/L; Neutrophils ≥ 1.0 X 109/Lb; Blasts 0%. Partial Remission: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by ≥ 50% over pretreatment but still \> 5%. Marrow Complete Remission: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR. HI Improvement: shown in increases in hemoglobin, platelet and neutrophil response.

Time frame:
Up to one year
Reported as:
Number · Percentage of Participants
The Overall Improvement Rate
Percentage of ParticipantsSchedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 Days
Overall Improvement Rate23.322.7
Complete Response16.30
Marrow Complete Response04.5
Partial Response04.5
Hematologic Improvement7.013.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Schedule A: SQ 3 Consecutive Days—18/43 (41.9%)43/43 (100%)
Schedule B: SQ Once Every 7 Days—10/22 (45.5%)22/22 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventSchedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 Days
PneumoniaInfections and infestations1/432/22
Febrile neutropeniaBlood and lymphatic system disorders2/430/22
Abdominal painGastrointestinal disorders2/430/22
Gastrointestinal hemorrhageGastrointestinal disorders2/430/22
AnemiaBlood and lymphatic system disorders0/431/22
CellulitisInfections and infestations1/431/22
SepsisInfections and infestations0/431/22
PneumonitisInfections and infestations0/431/22
AppendicitisInfections and infestations0/431/22
Escherichia bacteremiaInfections and infestations0/431/22
Most frequent other events
Showing 10 of 84
Most frequent other events
EventSchedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 Days
NeutropeniaBlood and lymphatic system disorders27/4315/22
AnemiaBlood and lymphatic system disorders24/439/22
ThrombocytopeniaBlood and lymphatic system disorders18/4312/22
LeukopeniaBlood and lymphatic system disorders18/4310/22
FatigueGeneral disorders17/4310/22
Decreaed appetiteMetabolism and nutrition disorders5/439/22
DyspneaRespiratory, thoracic and mediastinal disorders7/438/22
PyrexiaGeneral disorders14/436/22
NauseaGastrointestinal disorders12/433/22
ArthralgiaMusculoskeletal and connective tissue disorders12/433/22

Baseline characteristics

Modified Intent to Treat (mITT) Population

Age Continuous
Age Continuous(years)Schedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 DaysTotal
Mean66.9 ± 14.3970.5 ± 9.8668.2 ± 13.07
Sex: Female, Male
Sex: Female, Male(Participants)Schedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 DaysTotal
Female18220
Male252045
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Schedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 DaysTotal
Hispanic or Latino123
Not Hispanic or Latino422062
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Schedule A: SQ 3 Consecutive DaysSchedule B: SQ Once Every 7 DaysTotal
American Indian or Alaska Native112
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American505
White352055
More than one race000
Unknown or Not Reported112
08

Study locations

4 sites
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Landmark Medical Center
    Woonsocket, Rhode Island 02895, United States
  • Sarah Cannon Research
    Nashville, Tennessee 37203, United States
  • M. D. Anderson
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10;31(20):2548-53. doi: 10.1200/JCO.2012.44.6823. Epub 2013 Jun 3. PubMed 23733767 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008 and a primary completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2008
First posted
Feb 20, 2008
Start
May 2008
Primary completionActual
Mar 2012
Results first posted
Sep 18, 2013
Last update
Oct 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00619099
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 20, 2008
Start date
May 2008
Primary completion
Mar 2012
Results posted
Sep 18, 2013
Last update
Oct 24, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion